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Introduction
Hairy cell leukemia is a rare disease comprising about 2% of
lymphoid neoplasms.1 This neoplasm can be confused with
other hematologic diseases. Therefore, a differential diagnosis
must be performed between classic hairy cell leukemia, hairy
cell leukemia variant, and splenic marginal zone lymphoma
(SMZL).2 According to the World Health Organization (2008),
hairy cell leukemia variant was classiﬁed as a provisional
entity because it has clinical and pathological features that dif-
fer from classic hairy cell leukemia.3 Among these aspects are
morphological and immunophenotypic variations and resis-
tance to conventional treatment.1 Furthermore, patients with
hairy cell leukemia are treated with nucleoside analogs but
these drugs have a reduced response in hairy cell leukemia
variant and are even ineffective in some cases.3,4 An alterna-
tive for these patients is the association of nucleoside analogs
with the monoclonal antibody rituximab (anti-CD20).5 Thus,
due to differential treatment, the aim of this study was to
report a case of hairy cell leukemia variant and cover some
aspects related to the differential diagnosis between the clas-
sic and variant forms of the disease and SMZL. This study was
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Case  report
The case of a 74-year-old male patient is reported. The
presence of splenomegaly was observed since 2011, with
areas of infarction in the splenic periphery evidenced by
cholangiography and computed tomography. In 2012, due
to the persistence of splenomegaly, a complete blood count
and immunophenotyping by ﬂow cytometry were requested.
At this time, there was no lymphadenopathy. The blood
count showed alterations in red blood cells (poikilocyto-
sis, acanthocytes and squizocytes), anemia (hemoglobin
10.1 g/dL), thrombocytopenia (100 × 103/mL), and mild leuko-
cytosis (11.03 × 103/mL). A white blood cell differential
revealed the following: 2.86 × 103 neutrophils/mL (25.9%),
4.67 × 103 lymphocytes/mL (42.3%), 1.16 × 103 monocytes/mL
(10.5%), 1.73 × 103 eosinophils/mL (15.7%), 0.07 × 103ersitário Professor Polydoro Ernani de São Thiago, Universidade
, 88036-800 Florianópolis, SC, Brazil.
basophils/mL (0.6%) and 0.55 × 10 lymphocytes/mL (5.0%)
with cytoplasmic projections (Figure 1). Immunophenotyping
of peripheral blood (Figure 2) showed 23.2% of B lymphocytes
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Figure 1 – Small/intermediate-sized cells with moderate pale-gray cytoplasm, round/oval nuclei with smooth nuclear
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CD19+), monoclonal (sIg Kappa+), CD103+, CD11c+, CD20++,
D22+, IgM+/++ FMC7++, CD79b++, BCL2+ and no expression of
Ig Lambda, CD3, CD4, CD5, CD8, CD10, CD23, CD24, CD25,
D27, CD38, CD43, and CD123. Assessment of sIgD, sIgG, and
IgA expression on the pathological lymphocytes was not
erformed. The bone marrow was not evaluated and staging
as not performed during diagnosis. The treatment was four
ntravenous doses of rituximab 600 mg.  After the ﬁrst dose,
he patient was discharged and the response was monitored
n the outpatient clinic. At the end of the treatment, the
atient returned to the hospital and underwent a bone
arrow aspiration for immunophenotyping, myelogram, and
mmunohistochemistry. Immunophenotyping showed 1.1%
f B lymphoid cells with a similar phenotype to that found
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igure 2 – Representative dot plots of peripheral blood immunop
B) pathological cells (red) sIg Kappa+ and sIg Lambda− at diagno
iagnosis; (D) pathological cells (red) CD11c+ at diagnosis; (E) path
esidual disease; (F) pathological cells (red) CD103+ and CD11c+ inmferential hair-like and short, blunt cytoplasmic
at diagnosis (Figure 2). The myelogram showed hypercellu-
larity for the age, normal myeloid:erythroid ratio, as well
as normality for all other myelogram parameters. Immuno-
histochemistry revealed aggregates of small lymphocytes
CD20+ and DBA44−/+ and the result of TRAP staining was
indeterminate. Currently, the patient is being treated in the
outpatient clinic and undergoes periodic laboratory tests to
monitor the disease.Classic hairy cell leukemia, hairy cell leukemia variant, and
SMZL share some common features, including malignant
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ological cells (red) sIg Kappa+ and sIg Lambda− in minimal
 minimal residual disease.
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Table 1 – Comparison between classic hairy cell leukemia, hairy cell leukemia variant, and SMZL.
Classic hairy cell leukemia Hairy cell leukemia variant Splenic marginal zone lymphoma
Age Midlife Over 50 years Over 50 years
Gender prevalence Males No difference No difference
Granulocytopenia
and
monocytopenia
Present Usually absent Usually absent
Morphology Bone marrow and peripheral
blood: small- or medium-sized
cells; presence of oval or
bean-shaped nucleus;
homogeneous, less aggregated
chromatin; absent or
inconspicuous nucleoli; cytoplasm
is abundant, basophilic without
granules or villous projections
Bone  marrow cells: similar to the
classic hairy cell leukemia cells.
Peripheral blood: small cells;
round or oval nucleus;
nucleus:cytoplasm ratio is greater;
evident nucleolus; moderately
basophilic, villous cytoplasm
Bone  marrow and peripheral
blood: small- and medium-sized
cells; slightly basophilic
cytoplasm; moderately condensed
chromatin and indistinct nucleoli;
polar cytoplasmic projections
(villi) may appear
Spleen Inﬁltration of the red pulp Inﬁltration of the red pulp Inﬁltration of the white pulp
Bone marrow Dry tap Easy aspiration Easy aspiration
TRAP Positive Negative Negative
Annexin A1 Positive Negative Negative
Immunophenotype CD25+, CD103+, CD11c+, CD19+,
CD20+, CD22+, CD79a+, FMC7+,
sIg++, Kappa predominance, CD10
variable, CD79b−, CD5−, CD23−
CD25− CD103 variable, CD19+,
CD20+, CD22+, CD11c+, IgG+, IgA+,
FMC7+
CD25 variable, CD103, CD19+,
CD20+, CD22+, CD79a+, IgM+, IgD+,
CD5−, CD10−, CD23−, CD43−,
cyclin D1−lymphocytic inﬁltration in bone marrow and peripheral
blood, splenomegaly, and B lymphocytes with a similar
immunophenotype.5 Unlike classic hairy cell leukemia, the
variant form affects older individuals.1
Anemia and/or thrombocytopenia and leukocytosis are
common at diagnosis of hairy cell leukemia variant, while
pancytopenia, granulocytopenia, and monocytopenia are
more  common in classic hairy cell leukemia. The patient in
this study presented with anemia, thrombocytopenia, and
mild leukocytosis due to monocytosis, eosinophilia and the
presence of pathological lymphocytes.
Immunophenotyping by ﬂow cytometry contributes to
differential diagnosis, although it must also be associated
with immunohistochemistry and clinical data (Table 1). Clas-
sic hairy cell leukemia cells are always positive for CD25
and CD103 and hairy cell leukemia variant cells are always
negative for CD25 and occasionally positive for CD103. In
SMZL, on the other hand, CD103 is negative and CD25 may
be positive or negative.3,5 Classic hairy cell leukemia and
the variant form are also differentiated by the expression
of CD123, which is positive in the classic form and neg-
ative in the variant form.6 Evaluation of immunoglobulin
heavy chain isotype expression is another way to possi-
bly differentiate hairy cell leukemia variant from SMZL. An
unusual feature of hairy cell leukemia variant, not typically
observed in other B-cell lymphoproliferative disorders, is the
expression of pre-switched IgM/IgD and post-switched IgG/IgA
immunoglobulins by the same cells in approximately 40% of
cases. In contrast, SMZL cells characteristically express IgM
with IgD and lack IgG or IgA.7 Unfortunately in this case the
IgG, IgA and IgD immunoglobulins were not available for eval-
uation. Thus, the results of immunophenotypic analysis of
peripheral blood here were consistent with hairy cell leukemia
variant.In immunohistochemistry, DBA44 provides strong staining
for lymphocytes with cytoplasmic projections in tissues; how-
ever, it may also be present in normal B cells.3 Moreover, cells
from hairy cell leukemia variant patients rarely show TRAP
reactivity (unlike the classic form).1 In the patient of this study,
TRAP staining remained indeterminate; hence, it did not help
in the diagnosis. The morphology and phenotype conﬁrmed
the diagnosis of hairy cell leukemia variant.
When the patient returned to the hospital of the Uni-
versidade Federal de Santa Catarina (HU-UFSC) at the end
of treatment, the myelogram was hypercellular for his age,
but this alteration has no clinical relevance to his condition.
The presence of 1.1% of cells with a phenotype similar to
that found at diagnosis, as evidenced by immunophenotyping
of a bone marrow aspirate, indicates the presence of mini-
mal  residual disease (MRD). MRD is present in many  patients
treated for hairy cell leukemia; however, these patients may
have long-term survival. Treatment with Rituximab is used to
achieve complete remission, although the response is depend-
ent on how much bone marrow is involved and on the
characteristics of the individual.8
Conclusion
Hairy cell leukemia variant is a chronic lymphoprolifera-
tive disorder whose characteristics resemble the classic form
and SMZL, making differential diagnosis essential for ther-
apeutic follow-up, as hairy cell leukemia variant has a
decreased response to drugs prescribed for the classic form.
Immunophenotyping is a key tool for diagnosis, as some
markers are different between these neoplasms. Therefore,
immunophenotyping, clinical, morphological, and immuno-
histochemical manifestations must be considered in the
differential diagnosis.
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